In addition to haematological cancer cell targets, the killing of HER-2+ SK-BR-3 solid tumor cells with the trastuzumab hIgG1 μtp hexamer indicated that this technology could provoke increased CDC towards targets outside CD20 and malignancies outside of lymphoma. Here, ERBB2 is linked to lymphoma.